| Term 
 | Definition 
 
        | mechloroethamine, anthracyclines |  | 
        |  | 
        
        | Term 
 
        | IV, Intra-arterial, Intrathecally and oral administration routs |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | IV and oral administration |  | Definition 
 
        | cyclophosfamide, epipodopyllotoxins (oral is only 50% bioavail) |  | 
        |  | 
        
        | Term 
 
        | prevents multidrug resistance in tumor seen with anthracyclines |  | Definition 
 
        | verapamil; inhibits active transport by inhibiting ATP binding causing a dysfunctional pump |  | 
        |  | 
        
        | Term 
 
        | irreversible cardiotoxicity |  | Definition 
 
        | doxorubacin, daunorubacin |  | 
        |  | 
        
        | Term 
 
        | metal chelating agent that binds Fe/OH product used to mitigate anthracycling-associated cardiotoxicity |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Used to treat mitomycin-induced Hemolytic-uremic syndrome |  | Definition 
 
        | catopril, heparin and prednisone |  | 
        |  | 
        
        | Term 
 
        | FH2 rescue after high dose methotrexate |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | 6-MP-induced hyperuricemia |  | Definition 
 
        | lower dose and add allopurinol, no dose adjustment for 6-TG |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | mechloroethamine, anthracyclines (mitoxantrone less so), mitomycin, and vinca alkaloids |  | 
        |  | 
        
        | Term 
 
        | albumin-bound paclitaxel dosage form option for taxane-induced HS |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | cisplatin/ carboplatin and methotrexate (precipitation of 7OH metabolite) |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | doxorubacin (daunorubacin), carboplatin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | methotrexate, cytarabine, 6-MP (6-TG less so) |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | alkylating agents and cisplatin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | antimetabolites, except 5-FU |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | non-phase specific because it acts on both the DNA and RNA |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | cell cycle non-specific but maximal kill in G1 and S-phase |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | taxanes; paclitaxel and docetaxel |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | metabolite of CTP-11 (irinotecan) that is 1000-fold more potent, if there is mutation in conjugation step of metabolism this metabolite is not excreted causing toxicity |  | 
        |  |